GALMED PHARMACEUTICALS LTD. (EOCN) Return on equity 2016–2020
GALMED PHARMACEUTICALS LTD. (EOCN) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-65.2%FY2020 · since FY2016: -153.1% → -65.2%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2020 | -65.2% | -35.9 pp |
| FY2019 | -29.3% | -18.1 pp |
| FY2018 | -11.2% | +66.7 pp |
| FY2017 | -77.9% | +75.2 pp |
| FY2016 | -153.1% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice